혈액형 판정 시장 규모, 점유율 및 동향 분석 보고서 : 제품 유형별, 방법별, 검사 유형별, 지역별 및 부문별 예측(2026-2033년)

Blood Group Typing Market Summary

The global blood group typing market size was valued at USD 2.31 billion in 2025 and is projected to reach USD 5.59 billion by 2033, growing at a CAGR of 11.99% from 2026 to 2033. Market growth is driven by the rising burden of chronic diseases such as anemia, cancer, and blood disorders, which increases the need for frequent transfusions.

In addition, the growing number of surgical procedures, organ transplants, and trauma cases is further driving demand for accurate blood compatibility testing. The high burden of chronic diseases such as anemia, cancer, and hematological disorders is a significant driver of the blood group typing market, as these conditions often require frequent blood transfusions. For instance, according to a World Health Organization report published in 2025, anemia affects nearly 30% of women of reproductive age and around 40% of children under five globally, highlighting a substantial patient pool requiring transfusion support. Similarly, increasing cancer incidence and blood disorders such as thalassemia and sickle cell disease are contributing to repeated transfusion needs. This growing transfusion volume necessitates accurate ABO and Rh typing to ensure compatibility and prevent adverse reactions. Consequently, the rising prevalence of these chronic conditions is significantly accelerating demand for advanced blood group typing solutions worldwide.

The growing number of surgical procedures, organ transplants, and trauma cases is driving the demand for accurate blood compatibility testing, thereby supporting the growth of the blood group typing market. For instance, according to the World Health Organization (December 2023), around 1.2 million people die each year due to road traffic accidents, while many sustain non-fatal injuries and many require emergency transfusions. In addition, the number of organ transplant procedures has increased globally. According to an article published in PubMed in 2026, 173,727 solid organ transplants were performed worldwide in 2024, and these statistics were reported by the Global Observatory on Donation and Transplantation, an initiative of the WHO. These clinical situations require precise ABO and Rh typing and cross-matching to ensure patient safety. As the volume of surgeries and emergency care continues to rise, the need for reliable blood group typing solutions is also increasing.

Expanding blood donation programs and increasing transfusion volumes are contributing to the demand for routine blood group typing and compatibility testing. For instance, according to the statistics published by the World Health Organization in May 2025, over 118.5 million blood donations are collected globally each year, all of which require mandatory blood grouping and screening before use. In addition, advancements in molecular and automated typing technologies, including PCR-based genotyping, are improving accuracy and reducing turnaround time. The growing use of blood group typing in prenatal testing for diagnosing hemolytic disease of the newborn (HDN), along with stricter regulatory standards for transfusion safety, is further supporting the adoption of advanced typing solutions, thereby supporting overall market expansion. However, stringent approval processes and varying regulatory frameworks across regions can delay product launches and market entry.

Global Blood Group Typing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global blood group typing market report based on product, techniques, test type, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Consumables
• Instruments
• Services
• Techniques Outlook (Revenue, USD Million, 2021 - 2033)
• PCR-based and Microarray Techniques
• Assay-based Techniques
• Massively Parallel Sequencing Techniques
• Other Techniques
• Test Type Outlook (Revenue, USD Million, 2021 - 2033)
• Antibody Screening
• HLA Typing
• Cross-matching Tests
• ABO Blood Tests
• Antigen Typing
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Techniques
  • 1.2.3. Test Type
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Blood Group Typing Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising burden of chronic diseases.
    • 3.2.1.2. Growing number of surgical procedures.
    • 3.2.1.3. Expanding blood donation programs and rising transfusion volumes.
    • 3.2.1.4. Advancements in molecular and automated typing technologies.
  • 3.2.2. Market Restraint Analysis
  • 3.2.3. High cost of advanced technologies
  • 3.2.4. Limited skilled workforce and infrastructure
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Blood Group Typing Market: Product Business Analysis

• 4.1. Product Market Share, 2025 & 2033
• 4.2. Product Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Consumables
  • 4.4.1. Consumables Market, 2021 - 2033 (USD Million)
• 4.5. Instruments
  • 4.5.1. Instruments Market, 2021 - 2033 (USD Million)
• 4.6. Services
  • 4.6.1. Services Market, 2021 - 2033 (USD Million)

Chapter 5. Blood Group Typing Market: Techniques Business Analysis

• 5.1. Techniques Market Share, 2025 & 2033
• 5.2. Techniques Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Techniques, 2021 to 2033 (USD Million)
• 5.4. PCR-based and Microarray Techniques
  • 5.4.1. PCR-based and Microarray Techniques Market, 2021 - 2033 (USD Million)
• 5.5. Assay-based Techniques
  • 5.5.1. Assay-based Techniques Market, 2021 - 2033 (USD Million)
• 5.6. Massively Parallel Sequencing Techniques
  • 5.6.1. Massively Parallel Sequencing Techniques Market, 2021 - 2033 (USD Million)
• 5.7. Other Techniques
  • 5.7.1. Other Techniques Market, 2021 - 2033 (USD Million)

Chapter 6. Blood Group Typing Market: Test Type Business Analysis

• 6.1. Test Type Market Share, 2025 & 2033
• 6.2. Test Type Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Distribution channel, 2021 to 2033 (USD Million)
• 6.4. Antibody Screening
  • 6.4.1. Antibody Screening Market, 2021 - 2033 (USD Million)
• 6.5. HLA Typing
  • 6.5.1. HLA Typing Market, 2021 - 2033 (USD Million)
• 6.6. Cross-matching Tests
  • 6.6.1. Cross-matching Tests Market, 2021 - 2033 (USD Million)
• 6.7. ABO Blood Tests
  • 6.7.1. ABO Blood Tests Market, 2021 - 2033 (USD Million)
• 6.8. Antigen Typing
  • 6.8.1. Antigen Typing Market, 2021 - 2033 (USD Million)

Chapter 7. Blood Group Typing Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2025 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
• 7.4. North America
  • 7.4.1. North America Blood Group Typing Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Target Disease Prevalence
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Framework
    • 7.4.2.5. U.S. Blood Group Typing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Framework
    • 7.4.3.5. Canada Blood Group Typing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Framework
    • 7.4.4.5. Mexico Blood Group Typing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Blood Group Typing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Target Disease Prevalence
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Framework
    • 7.5.2.5. Uk Blood Group Typing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Framework
    • 7.5.3.5. Germany Blood Group Typing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Target Disease Prevalence
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement Framework
    • 7.5.4.5. France Blood Group Typing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Target Disease Prevalence
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Reimbursement Framework
    • 7.5.5.5. Italy Blood Group Typing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Target Disease Prevalence
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Reimbursement Framework
    • 7.5.6.5. Spain Blood Group Typing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Target Disease Prevalence
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement Framework
    • 7.5.7.5. Denmark Blood Group Typing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Target Disease Prevalence
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement Framework
    • 7.5.8.5. Sweden Blood Group Typing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Target Disease Prevalence
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Reimbursement Framework
    • 7.5.9.5. Norway Blood Group Typing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Blood Group Typing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Target Disease Prevalence
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Framework
    • 7.6.2.5. Japan Blood Group Typing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Framework
    • 7.6.3.5. China Blood Group Typing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Target Disease Prevalence
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Framework
    • 7.6.4.5. India Blood Group Typing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Target Disease Prevalence
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Framework
    • 7.6.5.5. Australia Blood Group Typing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Target Disease Prevalence
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement Framework
    • 7.6.6.5. South Korea Blood Group Typing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Target Disease Prevalence
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement Framework
    • 7.6.7.5. Thailand Blood Group Typing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Blood Group Typing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Target Disease Prevalence
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement Framework
    • 7.7.2.5. Brazil Blood Group Typing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Target Disease Prevalence
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement Framework
    • 7.7.3.5. Argentina Blood Group Typing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Middle East and Africa
  • 7.8.1. Middle East and Africa Blood Group Typing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Target Disease Prevalence
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement Framework
    • 7.8.2.5. South Africa Blood Group Typing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Target Disease Prevalence
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement Framework
    • 7.8.3.5. Saudi Arabia Blood Group Typing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Target Disease Prevalence
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Reimbursement Framework
    • 7.8.4.5. UAE Blood Group Typing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Target Disease Prevalence
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Reimbursement Framework
    • 7.8.5.5. Kuwait Blood Group Typing Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Grifols, S.A.
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Bio-Rad Laboratories, Inc.
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Merck KGaA
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Quotient, Ltd.
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Immucor, Inc.
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Danaher Corporation
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Novacyt Group
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Ortho Clinical Diagnostics
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Agena Bioscience, Inc.
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives